Access BR Monitor, Part No. 387620
Published May 24, 2017 · Recall initiated: April 13, 2017
Summary
FDA records medical device Class II recall Z-2074-2017, published May 24, 2017 and initiated April 13, 2017. Recalling firm: Beckman Coulter Inc.; Status: Terminated; Reported quantity: 45,278 units total (2,419 units in US); Lot: 623913, 625701, 628771, 630349, 633070 and All Future Lots. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Following biases observed in the results of the French National Quality Controls, Beckman Coulter has been informed that a study completed by the French Competent Authority Agence nationale de s®curit® du Medicament et des produits de sant® (ANSM) showed diagnosed cancer patients in non-remission of their metastatic disease, may have results below the upper reference limit (URL) of 31.3 U/mL as stated in the Access BR Monitor instructions for use (IFU).
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Beckman Coulter Inc.
- Distributor
- Affected geographies: Algeria, Australia, Austria, Bangladesh, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Ecuador, Egypt, El Salvador, France, Georgia, Germany, Ghana, Gibraltar, Greece, Guam, Guatemala, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Jordan, Kazakhstan, Kenya, Lebanon, Libya, Lithuania, Malaysia, Mayotte, Mexico, Morocco, Myanmar, Namibia, Nepal, Netherlands, New Zealand, Nigeria, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Rwanda, Saudi Arabia, Serbia, Sierra Leone, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom, United States, Venezuela, Vietnam, Zimbabwe
- Lot
- 623913, 625701, 628771, 630349, 633070 and All Future Lots
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDADxC 500 AU Clinical Chemistry Analyzers: 1. AU w/out ISE, Part No. C63519 2. AU w/ISE, Part No. C63520October 14, 2026
- FDADxC 500i Clinical Analyzer Modules: 1. DxC 500 AU Module w/ISE, DxC 500i, Part No. C63522 2. DxC 500 AUOctober 14, 2026
- FDABeckman Coulter DxC 500i Clinical Analyzer Modules using software version 1.5 or lower: 1) DxC 500 AU ModuleAugust 26, 2026
- FDABeckman Coulter DxC 500 AU Clinical Analyzer Modules using software version 1.5 or lower: 1) AU w/out ISE,August 26, 2026
- FDAPhilips V60 Ventilators, Material No. 850008, 1053613, 1053614, 1053615, 1053616, 1053617, 1076715, 1076716,May 24, 2017
- FDANavitrack System - OS Knee Universal, Stereotaxic instrumentMay 24, 2017
Questions about this recall
Was Access BR Monitor, Part No. 387620 recalled?
Yes. FDA published recall Z-2074-2017 on May 24, 2017. Reported hazard: Following biases observed in the results of the French National Quality Controls, Beckman Coulter has been informed that a study completed by the French Competent Authority Agence nationale de s®curit® du Medicament et des produits de sant® (ANSM) showed diagnosed cancer patients in non-remission of their metastatic disease, may have results below the upper reference limit (URL) of 31.3 U/mL as stated in the Access BR Monitor instructions for use (IFU).
What should I do if I have this product?
Voluntary: Firm initiated · Letter